Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin plus temozolomide chemoradiotherapy in newly diagnosed glioblastoma (DGM1-positive)
CTR20210055Phase 3Completed
- Sponsor
- Denovo Biopharma
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of enzastaurin in glioblastoma (GBM), Gliosarcoma (GS), sponsored by Denovo Biopharma. Started Jan 2021; status: completed.
02
Drugs
enzastaurin
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on CTR20210055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210055.